After three years of COVID-pandemic, and in that setting an once postponed and eventually cancelled European Association of Nuclear medicine (EANM) Focus 4 on molecular imaging and therapy in haematological tumours [1], the Nuclear Medicine community felt the longing for a live consensus meeting, with multidisciplinary stakeholders. As the clinical evidence was pointing to Theranostics in prostate cancer to be the most dynamic and rapidly evolving field in Oncology in the past 5 years, the choice for a new focus topic was obvious.
Oprea-Lager, D.-E., Maclennan, S., Dierckx, R., Fanti, S. (2024). The EANM Focus 5 consensus on ‘molecular imaging and theranostics in prostate cancer’: the future begins today. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 51(5), 1462-1463 [10.1007/s00259-023-06552-2].
The EANM Focus 5 consensus on ‘molecular imaging and theranostics in prostate cancer’: the future begins today
Fanti S.
2024
Abstract
After three years of COVID-pandemic, and in that setting an once postponed and eventually cancelled European Association of Nuclear medicine (EANM) Focus 4 on molecular imaging and therapy in haematological tumours [1], the Nuclear Medicine community felt the longing for a live consensus meeting, with multidisciplinary stakeholders. As the clinical evidence was pointing to Theranostics in prostate cancer to be the most dynamic and rapidly evolving field in Oncology in the past 5 years, the choice for a new focus topic was obvious.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
